NeuroBo Pharmaceuticals, Inc.

NRBO

US64132R4048

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 04/06/2024 am IST			5-day change	1st Jan Change
3.98 ^USD	+4.46%		-3.63%	+7.67%

22/05	NeuroBo Pharmaceuticals, Inc. Announces Pre-Clinical Data of DA-1241, a Novel G-Protein-Coupled Receptor 119 Agonist, in Combination with Semaglutide	CI
09/05	NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

NeuroBo Pharmaceuticals, Inc. Announces Resignation of Na Yeon Kim from the Board of Directors

September 20, 2023 at 01:45 am IST

On September 18, 2023, Ms. Na Yeon (Irene) Kim provided notice of her resignation from the Board of Directors of NeuroBo Pharmaceuticals, Inc., effective immediately.

Latest news about NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. Announces Pre-Clinical Data of DA-1241, a Novel G-Protein-Coupled Receptor 119 Agonist, in Combination with Semaglutide	22/05	CI
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target	08/05	MT
Sector Update: Health Care Stocks Mixed Wednesday Afternoon	17/04	MT
NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise	17/04	MT
NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity	17/04	CI
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash	01/04	CI
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
NeuroBo Pharmaceuticals to Continue Trial of Liver Disease Treatment Candidate -- Shares Down	13/03	MT
NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash	13/03	CI
NeuroBo Pharmaceuticals Names Marshall Woodworth Finance Chief	04/03	MT
NeuroBo Pharmaceuticals, Inc. Announces the Appointment of Marshall Woodworth as Chief Financial Officer	04/03	CI
NeuroBo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity	29/02	CI
US Equity Markets Close Higher Thursday Following Jobless Claims Data	02/02	MT
Sector Update: Health Care Stocks Rise in Late Afternoon	02/02	MT
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading	02/02	MT
Top Midday Gainers	02/02	MT
NeuroBo Gets FDA Clearance For DA-1726 Trial in Obesity; Shares Soar	01/02	MT
NeuroBo Shares Surge as Obesity Drug Moves to Phase I Trial	01/02	DJ
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment	01/02	CI
Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2A Clinical Trial Evaluating Da-1241 for the Treatment of Mash	18/01	CI
NeuroBo Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Price Rule	10/01	MT
NeuroBo Pharmaceuticals Submits New Drug Application to FDA for Phase 1 Trial of DA-1726 for Obesity; Shares Rise	28/12	MT
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity	28/12	CI
Top Premarket Gainers	13/12	MT

Chart NeuroBo Pharmaceuticals, Inc.

Duration

Period

More charts

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.

Sector

Biotechnology & Medical Research

Calendar

06/06/2024 - European Association for the Study of the Liver Congress - Abstract Number: 117

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.98 USD

Average target price

27.67 USD

Spread / Average Target

+595.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NEUROBO PHARMACEUTICALS, INC.	+7.67%	19.53M
VERTEX PHARMACEUTICALS INCORPORATED	+15.55%	121B
REGENERON PHARMACEUTICALS, INC.	+12.66%	107B
BIONTECH SE	-2.53%	24.82B
ARGENX SE	+1.34%	22.48B
GENMAB A/S	-9.91%	18.32B
WUXI APPTEC CO., LTD.	-42.28%	16.33B
BEIGENE, LTD.	-18.92%	15.31B
NEUROCRINE BIOSCIENCES, INC.	+6.19%	14.08B
SAREPTA THERAPEUTICS, INC.	+28.83%	11.74B

Bio Therapeutic Drugs